Latest industry research report on: RORgamma Modulators Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts
Retinoic
acid-related orphan nuclear receptor gamma (RORgamma) is a hot, but
difficult-to-drug target. More than 30 companies are active in drug
discovery and development. Technology companies with expertise in
discovery of drugs targeting nuclear hormone receptors are preferred
partners of Big Pharma and Biotech companies if they have identified
novel scaffolds of RORgamma antagonists. More than ten such
technology-pharma partnerships have been founded and already lead to
first successes. Three RORgamma antagonists (inverse agonists) are
already in clinical development and more to follow in 2016 and
thereafter.
The
report explains the scientific rationale for discovering antagonists of
RORgamma for treatment of autoimmune and inflammatory diseases, but
also of agonists of RORgamma for treatment of cancer. Clinical as well
as non-clinical data for target validation of RORgamma are provided.
Lead and up-side indications for development including the key product
profile are discussed. Potential safety concerns for novel RORgamma
modulators were identified.
Drug
discovery approaches of technology and pharmaceutical companies are
shown regarding strategies in partnering as well as in technologies
applied for structure-based drug discovery. Based on the experience in
the past, estimates of the required time from start of a discovery
program of RORgamma modulators until entry into human studies are
calculated. The competitive landscape of RORgamma modulator development
and discovery projects is analyzed and the profiles of companies
elaborated, separately for unpartnered technology or pharmaceutical
companies and for partnerships between technology and pharmaceutical
companies.
The report provides an understanding of:
- The target RORgamma
- Clinical and non-clinical target validation
- Clinical lead and up-side indications
- Drug discovery strategies and technologies
- Commercial value of drug discovery collaborations
- R&D timelines from start of screening to first-in-human studies
- Competitive landscape of RORgamma antagonists
- Agonists of RORgamma for cancer
- Profiles of unpartnered technology companies and lead projects
- R&D Partnerships and their discovery approaches and lead molecules
- Unpartnered pharmaceutical companies and their programs
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save time
and money for our clients. We are a one stop solution for all your
research needs, our main offerings are syndicated research reports,
custom research, subscription access and consulting services. We serve
all sizes and types of companies spanning across various industries.
Contact
Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
No comments:
Post a Comment